Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests.
Immunotherapy expert Pawel Muranski speaks about the new CAR-T therapy for leukemia and his work to bring T cell therapies to patients with a wide range of cancers.
Prakash Satwani, MD, leads NYP/CUMC's program in CAR-T therapy, a new treatment that uses a patient's own T cells to attack cancer.
Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network.
Advances in how the immune system can be harnessed to fight cancer offer new hope to patients with lung cancer.